Media Articles Related to Riastap (Fibrinogen Human)
NSAIDs Raise Bleeding, Thromboembolic Risk in Treated AF
Source: Medscape Anesthesiology Headlines [2014.11.18]
Even short-term use of nonsteroidal anti-inflammatory drugs may increase the bleeding and thromboembolic risk in patients with atrial fibrillation receiving antithrombotic treatment.
Medscape Medical News
Some Painkillers Tied to Bleeding Risk in Those With Abnormal Heartbeat
Source: MedicineNet Atrial Fibrillation Specialty [2014.11.18]
Title: Some Painkillers Tied to Bleeding Risk in Those With Abnormal Heartbeat
Category: Health News
Created: 11/17/2014 12:00:00 AM
Last Editorial Review: 11/18/2014 12:00:00 AM
NSAIDS associated with serious bleeding and thromboembolism in patients with atrial fibrillation
Source: Blood / Hematology News From Medical News Today [2014.11.17]
A study being published in Annals of Internal Medicine suggests that people with atrial fibrillation (AF) who take nonsteroidal anti-inflammatory drugs (NSAIDs) may be at risk for serious bleeding...
Source: MedicineNet Alternative Treatments for Hot Flashes Specialty [2014.07.22]
Title: Vaginal Bleeding
Category: Diseases and Conditions
Created: 7/4/2001 12:00:00 AM
Last Editorial Review: 7/22/2014 12:00:00 AM
Blood in the Stool (Rectal Bleeding)
Source: MedicineNet Anal Fissure Specialty [2014.07.16]
Title: Blood in the Stool (Rectal Bleeding)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/16/2014 12:00:00 AM
Published Studies Related to Riastap (Fibrinogen Human)
An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with
chronic obstructive pulmonary disease. 
The aims were to determine the effect of an oral inhibitor of the signaling
mediator p38 mitogen-activated protein kinase (GW856553, losmapimod) on sputum
neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic
obstructive pulmonary disease (COPD)... It was
concluded that oral losmapimod significantly reduced plasma fibrinogen in
patients with COPD.
The fibrinogen cleavage product Aalpha-Val360, a specific marker of neutrophil elastase activity in vivo. [2011.08]
BACKGROUND: Alpha-1-antitrypsin (A1AT) deficiency is the only recognised genetic risk factor for chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality worldwide. Since A1AT is the major inhibitor of neutrophil elastase (NE), this enzyme has become widely implicated in the pathogenesis of COPD in general; however, there is currently no specific biomarker for its pre-inhibition activity. Such a biomarker should be a measure of elastase-specific COPD disease activity with the potential to assess early targeted therapeutic intervention, in contrast to traditional and non-specific disease severity markers such as forced expiratory volume in 1 s... CONCLUSIONS: Aalpha-Val(360) represents the first specific footprint of pre-inhibition NE activity and is a potential biomarker of disease activity and progression in subjects with elastase-dependent COPD. TRIAL REGISTRATION: The EXACTLE study was registered in ClinicalTrials.gov as 'Antitrypsin (AAT) to Treat Emphysema in AAT-Deficient Patients'; ClinicalTrials.gov Identifier: NCT00263887.
De Marco Formula effectiveness as an adjunctive therapy to prevent infected ischemic diabetic foot amputation and reduce plasma fibrinogen. [2011.05]
BACKGROUND: De Marco Formula (DMF) is a new procaine chemical combination of Procaine HCl and polyvinylpyrrolidone. A prospective randomized controlled clinical trial demonstrated that infected ischemic diabetic foot treatment with DMF for 52 days as an adjuvant with conventional therapy reduced major amputations. OBJECTIVE: To evaluate the possible association of clinical effectiveness and plasma fibrinogen reduction with DMF therapy... CONCLUSION: DMF combined with conventional therapy for infected ischemic diabetic foot was associated with plasma fibrinogen decrease. Copyright (c) 2010 Tissue Viability Society. Published by Elsevier Ltd. All rights reserved.
Association between gamma' fibrinogen levels and inflammation. [2011.04]
The gamma' fibrinogen isoform produces clots that are stiffer and more resistant to breakdown than the more common fibrinogen isoform, gammaA. Increased levels of gamma' fibrinogen are associated with several forms of cardiovascular disease...
Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study. 
OBJECTIVE: To evaluate thromboelastographic parameters and fibrinogen levels in women treated with transdermal 17beta estradiol... CONCLUSIONS: Our data suggested that transdermal estrogen may not increase blood coagulability, but that it reduces fibrinogen levels in HT women.
Clinical Trials Related to Riastap (Fibrinogen Human)
Fibrinogen Concentrate (Human) âˆ’ Efficacy and Safety Study [Recruiting]
This is a multinational, multicenter, prospective, open-label historically controlled Phase
IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate
It is estimated that 150-300 patients in the U. S. suffer from afibrinogenemia. Substitution
with cryoprecipitate or alternative treatments have limited safety and efficacy.
The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen
Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma)
in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia).
Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used
as a historical control.
Haemocomplettan® P During Aortic Replacement [Recruiting]
The primary purpose is to show that administration of Haemocomplettan® P significantly
reduces the amount of blood products needed during aortic surgery.